Sarcoidosis

Sarcoidosis is a multisystem granulomatous disease of unknown etiology, defined pathologically by the presence of non-caseating granulomas in affected organs ^[10]D5. Also termed Boeck's disease or Besnier-Boeck-Schaumann disease, the condition can involve virtually any organ system, though the lungs, lymph nodes, skin, and eyes are most frequently affected. The diagnosis rests on compatible clinical and radiographic findings, histologic confirmation of non-caseating granulomas, and exclusion of alternative causes such as tuberculosis, fungal infection, or lymphoma (ATS/ERS/WASOG consensus statement).

Scadding Radiographic Staging

The most widely used classification for pulmonary sarcoidosis is the Scadding system, based on chest radiography. The stage at presentation offers a crude prognostic framework, with higher stages generally associated with worse outcomes and greater likelihood of persistent disease.

Stages are not necessarily sequential; some patients progress from stage I to II, while others present with stage III or IV. The Scadding system correlates with the likelihood of spontaneous remission: stage I disease resolves in up to of patients, whereas stage IV disease almost never resolves spontaneously and requires treatment ^[10]D5. Importantly, the system does not capture the functional impact of disease, symptoms and pulmonary function tests are independent of the radiographic stage, and it has largely been supplanted by high-resolution CT in clinical decision-making, though it remains a universal shorthand for disease extent.

Diagnostic Criteria

The diagnostic criteria for sarcoidosis have evolved from clinical-pathologic consensus. The ATS/ERS/WASOG statement emphasizes three pillars: (1) a compatible clinical and radiographic picture, (2) histologic evidence of non-caseating granulomas, and (3) exclusion of other granulomatous diseases (e.g., tuberculosis, fungal infections, berylliosis, hypersensitivity pneumonitis ). In the absence of a tissue biopsy, a presumptive diagnosis can be made in patients with classic manifestations, such as Löfgren syndrome ( erythema nodosum , bilateral hilar adenopathy, and arthralgias), along with supportive imaging and laboratory findings.

Pearl: The Scadding stage at initial diagnosis provides a crude but useful prognostic framework for pulmonary sarcoidosis, stage I has an chance of spontaneous remission, while stage IV carries a < chance of remission and mandates treatment consideration.

From the established definition, the disease burden of sarcoidosis varies markedly across populations, reflecting complex genetic-environmental interactions. Incidence and prevalence differ substantially by geography, race, and age, though recent systematic analyses have sharpened the focus on specific demographic and exposure-related risk factors.

Incidence and Prevalence

Pooled estimates of overall sarcoidosis incidence are not available from the current evidence, but several key prevalence figures emerge. In a meta-analysis of 51 studies (6093 patients), the pooled relapse prevalence after treatment reduction or discontinuation was 39% (95% CI: 0.33-0.45) with substantial heterogeneity (I² = 94%) ^[11]A1a. Among patients with pre-existing sarcoidosis treated with immune checkpoint inhibitors, flare prevalence was **19.6% **, with low heterogeneity ^[18]B2a. In melanoma patients on immunotherapy, drug-induced sarcoidosis-like reaction (DISR) occurred in 9% of cases ^[17]B3b. Clinical cardiac involvement is reported in approximately 5% of sarcoidosis patients, but atrial arrhythmias may occur in up to 40% of those with cardiac sarcoidosis ^[14]C4.

Demographic Distribution

Sex and age patterns vary by phenotype. In neurosarcoidosis with anterior visual pathway involvement, females are predominantly affected ^[6]A1a. Isolated cardiac sarcoidosis affects both sexes equally, with most patients aged 55-65 years ^[7]C4. Black race is a significant risk factor for relapse: compared with White race, the odds of relapse are 2.48 times higher (log OR 0.91, p < 0.01) ^[11]A1a.

Environmental and Occupational Risk Factors

A systematic review and meta-analysis of 13 studies identified five categories of occupational toxic particles associated with pulmonary sarcoidosis risk ^[12]B2a. The evidence is summarized in the table below.

Table: Occupational exposures associated with pulmonary sarcoidosis (adapted from ^[12]B2a)

Prognostic Implications

Sarcoidosis-associated heart failure carries a particularly poor prognosis. In a propensity-matched nationwide cohort, 1-year all-cause mortality was 12.9% in sarcoidosis-associated HF versus 8.6% in dilated cardiomyopathy-HF (HR 1.51) and 14.8% versus 9.7% in ischemic heart disease-HF (HR 1.58) ^[13]B2b.

Temporal Trends and Special Populations

No temporal trend data were reported in the included studies. However, the rising use of immune checkpoint inhibitors has created a new at-risk population for DISR and sarcoidosis reactivation. In patients with pre-existing sarcoidosis, ICI therapy leads to flare in approximately one in five patients, though flares are generally mild to moderate and manageable with corticosteroids ^[18]B2a.

Pearl: When evaluating a patient with suspected sarcoidosis, inquire about occupational exposures to silica, pesticides, mould, and World Trade Center dust, these are among the strongest environmental risk factors identified to date. In Black patients, anticipate a higher risk of relapse after treatment reduction, and consider closer monitoring ^{[11]A1a[12]B2a}.

Building on the global distribution of sarcoidosis, its etiology remains incompletely understood but is now recognized to involve a convergence of environmental exposures, genetic predisposition, and iatrogenic triggers. The resulting immunologic cascade culminates in non-caseating granuloma formation, the histologic hallmark of the disease.

Causative Factors

Environmental and Occupational Exposures

A systematic review and meta-analysis identified five categories of toxic particles associated with increased sarcoidosis risk: chemicals, inorganic dusts, metals, mixed dusts and fumes, and organic dusts ^[12]B2a. Specific agents with robust evidence include silica, pesticides, mould/mildew, and World Trade Center (WTC) dust ^[12]B2a. Sensitivity analyses confirmed the association for WTC dust and mould, whereas the link to silica was attenuated in high-quality studies, suggesting residual confounding ^[12]B2a. Interestingly, gold exposure was identified as a protective factor, though the mechanism is unclear ^[12]B2a.

Drug-Induced Sarcoidosis-Like Reactions (DISR)

A growing number of biologic agents paradoxically trigger granulomatous inflammation that mimics sarcoidosis. Anti-TNF agents ( infliximab , adalimumab ) are the most frequently implicated, with a median time to onset of 21 months and extrathoracic involvement in 76.7% of cases ^[30]C4. Discontinuation of the culprit drug is recommended, and moderate-to-severe cases often require specific treatment ^[30]C4. Other agents include tocilizumab (IL-6 receptor blockade) ^[29]C4, dupilumab (IL-4/IL-13 receptor blockade) ^[22]D5, and immune checkpoint inhibitors (ICIs) ^[18]B2a. In a pooled analysis of cancer patients with pre-existing sarcoidosis treated with ICIs, 93.0% showed no reactivation; the pooled flare prevalence was **19.6% **, with mild-to-moderate severity and no fatal outcomes ^[18]B2a. Flare rates varied by ICI class: anti-CTLA-4 25%, anti-PD-1/PD-L1 14.3%, mixed regimens 3.1% ^[18]B2a.

Genetic Susceptibility

Genetic factors play a critical role. HLA class II alleles (e.g., HLA-DRB1*03, *11, *14) are the most consistently associated ^[28]D5. Less common but highly penetrant are NOD2 gene variants: gain-of-function mutations cause Blau syndrome, an autosomal dominant autoinflammatory disease with widespread granulomatous inflammation ^[24]D5[27]D5. Hypomorphic NOD2 variants are associated with Crohn's disease and Yao syndrome, a multisystem disorder with recurrent fever, dermatitis, and arthritis ^[27]D5. The NOD2 protein is an intracellular sensor of bacterial muramyl dipeptide, and its altered signaling may contribute to granuloma formation ^[24]D5.

Type I Interferonopathies

Patients with systemic lupus erythematosus, systemic sclerosis, and Sjögren's disease, conditions driven by dysregulated type I interferon (IFN-I) signaling, have a significantly increased risk of developing cutaneous sarcoidosis ^[19]B2b. This association supports the hypothesis that IFN-I pathway activation contributes to sarcoidosis pathogenesis ^[19]B2b.

Infectious Triggers

The etiologic role of specific microbes (e.g., Propionibacterium acnes, mycobacteria, fungi) remains unconfirmed. Gut and lung microbiota composition differs in sarcoidosis patients compared to healthy controls, but whether these changes are causal or secondary is unclear ^[26]D5. Current evidence does not support routine antimicrobial therapy ^[28]D5.

Pathogenesis

The transition from trigger to clinical disease follows a stepwise immunologic cascade:

1. Antigen exposure in a genetically susceptible host → antigen-presenting cells (macrophages, dendritic cells) process and display the offending antigen.
2. T cell activation: CD4+ T cells differentiate into Th1 and Th17 subsets, driven by IL-12 and IL-23 from innate cells ^[28]D5. IFN-γ and TNF-α are the dominant effector cytokines.
3. Macrophage recruitment and activation: IFN-γ activates macrophages, which fuse to form multinucleated giant cells. Together with epithelioid histiocytes, they organize into non-caseating granulomas ^[28]D5.
4. Persistent inflammation: Failure of regulatory T cells to suppress the response, or ongoing antigenic stimulation, leads to chronic granulomatous inflammation. NOD2 signaling and type I interferon pathways amplify the inflammatory milieu ^{[24]D5[19]B2b}.
5. Organ dysfunction: Granulomas disrupt normal architecture, causing fibrosis, obstruction, or functional impairment. In the lung, this manifests as restrictive physiology; in the heart, conduction abnormalities or cardiomyopathy ^[25]D5.

Recent proteomic analysis of plasma extracellular vesicles in sarcoidosis patients identified 97 differentially expressed proteins with AUC > 0.75, implicating pathways such as clathrin-mediated endocytosis, Hsp90 chaperone cycle, and spliceosome ^[23]B3b. These findings suggest that vesicle-mediated intercellular communication contributes to disease propagation.

Controversies and Guideline Disagreement

Pearl: When a patient presents with granulomatous inflammation and a history of biologic therapy (especially anti-TNF, anti-IL-6, or anti-IL-4/IL-13 agents), drug-induced sarcoidosis-like reaction must be the first consideration, discontinuation of the culprit drug often leads to resolution without immunosuppression.

The granulomatous inflammation that characterizes sarcoidosis can affect virtually any organ, with the lungs and thoracic lymph nodes involved in over 90% of patients. The clinical presentation is highly variable, ranging from asymptomatic incidental findings to progressive organ failure. This section details the key features by organ system, emphasizing patterns that should raise suspicion for sarcoidosis.

Pulmonary

Pulmonary involvement dominates the clinical picture. Patients present with cough, dyspnea, and chest discomfort, often insidious in onset. The multinational Delphi consensus defined high-resolution CT phenotypes that guide diagnosis ^[37]D5. Typical findings include bilateral hilar lymphadenopathy with or without parenchymal involvement (stages I-IV). Symptoms may be minimal despite radiographic abnormalities.

Cutaneous

Cutaneous sarcoidosis provides visible clues to systemic disease. Erythema nodosum , tender red nodules on the shins, is a hallmark of acute sarcoidosis, often accompanying Löfgren syndrome. Lupus pernio, a violaceous indurated plaque on the nose, cheeks, or ears, signals chronic fibrotic disease and is associated with pulmonary fibrosis ^[39]D5. Other lesions include papules, plaques, and scar infiltration. Sarcoidosis-lymphoma syndrome can present with cutaneous lesions after lymphoma treatment, requiring biopsy to exclude recurrence ^[40]C4.

Ocular

Ocular involvement occurs in up to 30% of patients. Anterior uveitis is most common, but posterior uveitis, panuveitis, and optic nerve involvement occur. In neurosarcoidosis with anterior visual pathway involvement (NSAVP), 94% present with visual loss, 78% have no prior systemic symptoms, and 46% have bilateral involvement ^[6]A1a. Combination steroid and immunosuppressive therapy reduces the incidence of no light perception (1% vs 16% with steroids alone) and lowers relapse (16% vs 40%) ^[6]A1a.

Cardiac

Cardiac sarcoidosis (CS) is frequently underdiagnosed. The clinical spectrum ranges from asymptomatic conduction abnormalities to life-threatening ventricular arrhythmias and heart failure ^[34]D5. Isolated cardiac sarcoidosis (iCS) is the most diagnostically challenging form, requiring exclusion of extracardiac disease and multimodality imaging (CMR with LGE, FDG-PET) ^[9]D5. Endomyocardial biopsy has limited sensitivity due to patchy granuloma distribution ^[34]D5. Red flags include unexplained atrioventricular block, ventricular tachycardia, or heart failure with preserved ejection fraction in a young to middle-aged adult.

Neurologic

Neurologic involvement (neurosarcoidosis) affects 5-15% of patients. Cranial neuropathies , especially facial nerve palsy, are common. Hypothalamic-pituitary sarcoidosis presents with polydipsia, polyuria, memory impairment, and gonadal dysfunction; MRI shows expansile, homogeneously enhancing lesions in the infundibulum and inferior hypothalamus ^[33]B3b. Symptomatic hypothalamic-pituitary disease has a high relapse risk (12/19 vs 3/12 asymptomatic) and often requires two or more lines of maintenance therapy, with TNF inhibitors successful in 66.7% ^[33]B3b. Longitudinally extensive transverse myelitis (from cervical to mid-thoracic cord) with mediastinal lymphadenopathy is a diagnostic clue ^[44]C4. Small fiber neuropathy (SFN) is common, with an estimated prevalence of 33-86%; symptoms include pain, numbness, fatigue, and autonomic dysfunction ( gastrointestinal dysmotility, palpitations, sexual dysfunction) ^[38]D5. Diagnosis of SFN relies on clinical signs, normal nerve conduction studies, and either abnormal quantitative sensory testing or decreased intraepidermal nerve fiber density on skin biopsy ^[38]D5.

Other Organ Involvement

• Renal: Hypercalcemia , acute or chronic kidney injury, and rarely end-stage renal disease requiring transplant. Recurrence in transplanted kidneys can manifest as hypercalcemia ^[41]C4.
• Hepatic: Granulomatous hepatitis, often asymptomatic, rarely causing cholestasis or cirrhosis.
• Musculoskeletal: Arthralgias, especially in acute sarcoidosis; muscle involvement is rare.
• Hematologic: Lymphadenopathy, splenomegaly, and rarely hypersplenism.
• Salivary/lacrimal glands: Parotid enlargement, which may be part of Heerfordt syndrome (parotitis, uveitis, facial nerve palsy, fever).

Phenotypic Variants

Red Flags

• Respiratory compromise: Acute worsening of dyspnea with FVC < 15 mL/kg suggests impending respiratory failure requiring intubation.
• Cardiac symptoms: Syncope, palpitations, or unexplained heart failure - prompt ECG and cardiac imaging.
• Neurologic progression: Rapid onset of paraparesis, urinary retention, or cranial nerve deficits - urgent MRI and CSF analysis.
• Hypercalcemia: Severe hypercalcemia (>14 mg/dL) can cause renal failure; treat with hydration and corticosteroids.

Pearl: In any patient with unexplained uveitis, cardiac conduction block, or bilateral hilar lymphadenopathy, specifically ask about small fiber neuropathy symptoms (fatigue, pain, dysautonomia) - SFN is present in up to 86% of sarcoidosis patients and is a major driver of disability ^[38]D5.

The diverse clinical presentations of sarcoidosis, from asymptomatic hilar lymphadenopathy to life-threatening cardiac or neurologic involvement, demand a systematic diagnostic approach that begins with histologic confirmation. The diagnosis rests on three pillars: a compatible clinical and radiographic picture, demonstration of non-caseating granulomas, and exclusion of alternative causes ^[1]A1a[9]D5.

Histologic Confirmation

Biopsy of the most accessible involved site remains the gold standard. For patients with mediastinal lymphadenopathy, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the traditional first-line technique, but newer methods improve yield. A network meta-analysis of 35 studies found that EBUS-guided intranodal forceps biopsy (EBUS-IFB) (RR 3.50) and EBUS-guided transbronchial mediastinal cryobiopsy (EBUS-TMC) (RR 3.52) significantly outperform conventional transbronchial lung biopsy (TBLB) ^[1]A1a. Surface-under-the-cumulative-ranking (SUCRA) scores place EBUS-IFB (0.912) and EBUS-TMC (0.910) at the top, followed by EBUS-guided core needle biopsy (0.587) and standard EBUS-TBNA (0.560) ^[1]A1a. All procedures have a favourable safety profile. When skin, peripheral lymph nodes, or other extrapulmonary sites are involved, biopsy there is simpler and highly specific. In cardiac sarcoidosis , endomyocardial biopsy (EMB) has limited sensitivity (22.2% in the ILLUMINATE-CS registry) ^[55]B2b. Predictors of positive EMB include thicker basal interventricular septum (optimal cutoff 8.9 mm), ≥10 positive segments on 18F-FDG-PET, and B-type natriuretic peptide >155.0 pg/mL ^[55]B2b. Electroanatomic mapping-guided biopsy may improve histologic yield ^[9]D5.

Imaging

Chest radiography is typically the first imaging modality, characteristically showing bilateral hilar lymphadenopathy with or without parenchymal opacities. High-resolution computed tomography (HRCT) of the chest better defines parenchymal involvement (nodules, septal thickening, fibrosis) and guides biopsy. 18F-FDG-PET/CT detects active inflammation throughout the body and is particularly valuable in cardiac sarcoidosis, where it can identify early inflammatory disease before structural changes occur ^[10]D5[54]D5. Cardiac magnetic resonance with late gadolinium enhancement provides complementary assessment of fibrosis and scar ^[9]D5. In neurosarcoidosis , MRI with gadolinium most often reveals expansile, homogeneously enhancing lesions centered on the infundibulum (96.6%) and inferior hypothalamus (96.6%), with frequent additional inflammatory foci in the neuraxis (93.1%) ^[33]B3b. The “trident sign” on axial postcontrast spine MRI is characteristic of sarcoid myelopathy ^[8]D5.

Laboratory Studies

No single laboratory test is diagnostic, but several support the evaluation. Serum angiotensin-converting enzyme (ACE) is elevated in approximately 50-60% of patients but has limited sensitivity and specificity; a normal level does not exclude active disease. Soluble interleukin-2 receptor (sIL-2R) is more sensitive and reflects T-cell activation. Hypercalcemia occurs in 10-20% of patients overall but was present in 45% of a renal sarcoidosis cohort ^[49]B3b. Serum creatinine and urinalysis are mandatory to screen for renal involvement. In the renal sarcoidosis cohort, median serum creatinine at diagnosis was 242 µmol/L and median eGFR 23 mL/min/1.73 m² ^[49]B3b.

Diagnostic Algorithm

The diagnostic workup follows a stepwise approach: Step 1 - Clinical suspicion based on symptoms, signs, and initial imaging (chest radiograph, CT). Step 2 - Biopsy of the most accessible involved site. For mediastinal lymphadenopathy, EBUS-IFB or EBUS-TMC is preferred given their superior yield ^[1]A1a. Step 3 - If initial biopsy is nondiagnostic but clinical suspicion remains high, consider repeat biopsy using an alternative technique or a different site. Step 4 - Exclude alternative causes of granulomatous inflammation, including tuberculosis, fungal infections, lymphoma, berylliosis, and hypersensitivity pneumonitis . In silica-exposed workers, systematic integration of occupational history, serial HRCT, and histopathology is necessary to distinguish silicosis , sarcoidosis, and silicosarcoidosis ^[43]C4. Step 5 - In suspected isolated cardiac sarcoidosis, apply a probability-based multimodality framework incorporating cardiac MRI, FDG-PET, and EMB if indicated ^[9]D5[10]D5.

Pearl: EBUS-guided intranodal forceps biopsy (EBUS-IFB) offers the highest diagnostic yield for mediastinal lymphadenopathy in sarcoidosis, with a relative risk of 3.50 compared to conventional TBLB ^[1]A1a.

Establishing the diagnosis of sarcoidosis requires not only compatible clinical and histopathologic findings but also the rigorous exclusion of alternative diagnoses that can produce identical granulomatous inflammation ^[28]D5. The differential is broad, varying by organ system, and failure to consider it risks misdiagnosis and inappropriate treatment ^[58]D5.

Pulmonary and Mediastinal

Tuberculosis (TB) and nontuberculous mycobacterial infection are the most critical mimics because they produce noncaseating granulomas in up to one-third of sarcoid biopsies ^[58]D5. Distinguishing features include caseating necrosis on histology, positive acid-fast bacilli smears, cultures, or nucleic acid amplification tests, and a strong epidemiologic risk. Berylliosis (chronic beryllium disease) is clinically and radiographically indistinguishable from pulmonary sarcoidosis ; a history of occupational exposure to beryllium and a positive beryllium lymphocyte proliferation test (BeLPT) are required to differentiate ^[43]C4. Silicosis and the hybrid entity silicosarcoidosis present with overlapping HRCT patterns (nodular opacities, upper-lobe fibrosis) and functional decline; systematic assessment integrating occupational history, serial imaging, and histopathology is essential ^[43]C4. Lymphoma , particularly Hodgkin lymphoma, can cause bilateral hilar and mediastinal lymphadenopathy; PET/CT shows FDG-avid nodes, but biopsy reveals Reed-Sternberg cells, not granulomas. The sarcoidosis-lymphoma syndrome describes sarcoidosis preceding, concurrent with, or following lymphoma, and skin lesions after lymphoma treatment may represent sarcoidosis rather than recurrence, mandating histologic confirmation ^[40]C4.

Cutaneous

Lupus vulgaris , cutaneous TB, and fungal infections can mimic sarcoid skin lesions. The presence of necrosis or organisms on special stains distinguishes them. As noted, in patients with prior lymphoma, new skin lesions should be biopsied to exclude recurrence versus cutaneous sarcoidosis ^[40]C4. Calciphylaxis , though rare, can initially present as indurated plaques mimicking cellulitis or sarcoidosis, particularly in patients with end-stage renal disease ^[50]C4.

Cardiac

Arrhythmogenic right ventricular cardiomyopathy (ARVC) and giant cell myocarditis (GCM) are the two most important cardiac mimics. Compared to ARVC, cardiac sarcoidosis (CS) patients are older (>40 years), have longer PR interval and QRS duration, lower left ventricular ejection fraction, and septal late gadolinium enhancement on cardiac MRI; FDG-PET shows focal uptake in up to 90% of CS cases ^[3]B2a. Importantly, 62.5%-100% of CS patients fulfill the 1994 or 2010 International Task Force criteria for ARVC, so these criteria should not be used to discriminate ^[3]B2a. GCM presents with a fulminant course, diffuse myocardial necrosis, eosinophilic infiltrate, and a CD8+ T-cell predominant response, whereas CS is more indolent with well-formed nonnecrotizing granulomas and a CD4+ predominance ^[36]D5. Endomyocardial biopsy, though limited by sampling error, remains the gold standard for differentiation ^[57]D5.

Neurologic

Neurosarcoidosis diagnosis is especially challenging because its clinical and imaging features overlap with multiple sclerosis , CNS lymphoma, and infectious meningoencephalitis (TB, fungal, viral) ^[56]D5. Cerebrospinal fluid analysis typically shows lymphocytic pleocytosis and elevated protein; oligoclonal bands may be present. MRI findings (leptomeningeal enhancement, periventricular lesions) are nonspecific. The diagnosis relies on supportive ancillary tests and exclusion of alternatives in a patient with known extraneural sarcoidosis ^[56]D5.

Ocular

Uveitis in sarcoidosis must be differentiated from infectious causes (TB, syphilis, toxoplasmosis , herpes viruses) and noninfectious conditions ( Vogt-Koyanagi-Harada disease , Behçet's disease , multiple sclerosis). A thorough history, serologic testing (syphilis, toxoplasma, ANCA, HLA-B27), and aqueous/vitreous sampling for PCR may be required.

Other Systemic Considerations

Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) produce granulomatous inflammation; the presence of c-ANCA (anti-PR3) or p-ANCA (anti-MPO) plus vasculitic features (cavitary lung nodules, sinonasal disease, renal involvement) helps distinguish them. Drug-induced granulomatosis can occur with TNF inhibitors, immune checkpoint inhibitors, and interferon therapy; a temporal relationship to drug exposure is key. Inborn errors of immunity such as chronic granulomatous disease and Blau syndrome should be considered in children or those with recurrent infections and family history ^[28]D5.

Pearl: Before initiating immunosuppression for suspected sarcoidosis, always exclude tuberculosis (culture, PCR, IGRA) and other infections, because corticosteroids can unmask or disseminate latent infection, a treatable mimic is far more dangerous than a missed diagnosis of sarcoidosis.

Once the diagnosis of sarcoidosis is established through the workup outlined in the preceding section, the decision to initiate therapy is guided by disease activity, symptom burden, and the presence of organ-threatening or progressive disease. Not all patients require treatment: asymptomatic pulmonary sarcoidosis with stable lung function, incidentally found cutaneous lesions, or isolated hilar adenopathy often warrant observation alone, with reassessment every 3-6 months.

Indications for Treatment

Treatment is indicated for any of the following scenarios:

• Pulmonary involvement causing symptoms (cough, dyspnea, chest pain) or objective decline in forced vital capacity (FVC) or diffusing capacity. The PREDMETH trial established that first-line therapy with either prednisone or methotrexate is appropriate for patients with active pulmonary disease requiring intervention ^[60]A1b.
• Cardiac sarcoidosis with evidence of arrhythmia, heart failure, or myocardial inflammation on fluorodeoxyglucose-positron emission tomography (FDG-PET). Corticosteroids remain the mainstay, but the ongoing REPAIR-CS trial (NCT06660732) is evaluating the IL-1 trap rilonacept as a corticosteroid-sparing option ^[48]D5.
• Neurologic involvement ( neurosarcoidosis ) presenting with symptoms such as cranial neuropathy, myelopathy, or aseptic meningitis. Combination therapy with corticosteroids and an immunosuppressant (e.g., methotrexate or infliximab ) is associated with lower relapse rates (16% vs 40% with steroids alone) and better visual outcomes in anterior visual pathway disease ^{[6]A1a[61]B2b}.
• Ocular sarcoidosis with uveitis that is progressive or sight-threatening. Systemic therapy is required when topical corticosteroids fail or when posterior segment involvement is present.
• Cutaneous sarcoidosis that is disfiguring, painful, or refractory to topical treatments.

Treatment Goals

The primary goals of therapy are: (1) symptom relief, (2) preservation or improvement of organ function, (3) minimization of corticosteroid exposure and its long-term toxicities, and (4) prevention of relapse. A successful response is typically defined as improvement in FVC by ≥5 percentage points, resolution of inflammatory activity on FDG-PET, or ability to taper prednisone to ≤5 mg/day while maintaining disease control ^{[60]A1b[61]B2b}.

Shared Decision-Making

Choice of first-line agent reflects patient preferences regarding side-effect profiles. Prednisone is associated with weight gain, insomnia, and increased appetite; methotrexate with nausea, fatigue, and transient liver function abnormalities ^[60]A1b. For patients with pulmonary sarcoidosis, methotrexate is noninferior to prednisone for improving FVC at 24 weeks (adjusted between-group difference -1.17 percentage points; 95% CI -4.27 to 1.93) and offers a more favorable long-term metabolic profile ^[60]A1b. In neurosarcoidosis, infliximab demonstrates a 100% response rate at 12 months and a lower relapse rate (6%) compared with cyclophosphamide (56%) or methotrexate (38%), though the difference in relapse did not reach statistical significance (p=0.06) ^[61]B2b. Rituximab is reserved for patients with multiple cranial neuropathies refractory to other agents, as it fails in most cases (73.7%) ^[62]B2b.

Controversies and Guideline Disagreement

Pearl: For pulmonary sarcoidosis, methotrexate is a noninferior first-line alternative to prednisone with a distinct side-effect profile, while in neurosarcoidosis, infliximab and methotrexate offer effective relapse prevention with lower toxicity than cyclophosphamide ^{[60]A1b[61]B2b}.

The decision to initiate pharmacologic therapy rests on the indications outlined in the preceding section, organ-threatening or symptomatic disease, and triggers a choice between corticosteroids and methotrexate as first-line agents. The PREDMETH trial (N=138) now provides level 1b evidence that methotrexate is noninferior to prednisone for pulmonary sarcoidosis : the mean change in %‑predicted FVC at 24 weeks was 6.75 percentage points (95% CI 4.50-8.99) with prednisone and 6.11 percentage points (95% CI 3.72-8.50) with methotrexate, for an adjusted between-group difference of -1.17 percentage points (95% CI -4.27 to 1.93) ^[60]A1b. Adverse events differed in pattern: prednisone caused weight gain, insomnia, and increased appetite; methotrexate caused nausea, fatigue, and abnormal liver function tests, but the overall incidence was similar ^[60]A1b. These data challenge the traditional paradigm of corticosteroids as mandatory first-line therapy and support shared decision-making that weighs the toxicity profile of glucocorticoids against the slower onset of methotrexate.

Step 1: First-Line Therapy, Corticosteroids or Methotrexate

For patients requiring treatment, either prednisone 0.5-1 mg/kg/day (typical starting dose 20-40 mg/day) or methotrexate 10-15 mg once weekly (oral or subcutaneous) is appropriate ^{[49]B3b [60]A1b}. The PREDMETH regimen used a prespecified tapering schedule for prednisone and a fixed weekly dose for methotrexate; the trial did not report the exact dose of methotrexate, but clinical practice follows the label. Corticosteroids produce more rapid symptom relief (within weeks), whereas methotrexate may require 8-12 weeks for full effect. The 2025 WASOG statement and recent reviews advocate earlier adoption of steroid-sparing strategies to avoid the cumulative toxicity of glucocorticoids ^{[69]D5 [75]D5 [76]D5}.

Corticosteroid toxicity is substantial and durable. In an international survey of 1,937 patients, ever use of oral corticosteroids was associated with 1.3 more comorbidities (95% CI 0.8-1.9) compared with never use, including increased odds of osteoporosis (OR 3.8), diabetes (OR 2.7, 95% CI 1.2-6.0), infections (OR 2.1, 95% CI 1.1-4.0), and 5.9 kg net weight gain (95% CI 3.8-8.0 kg) ^[72]C4. These adverse effects persisted even after discontinuation, underscoring the imperative to minimize cumulative exposure.

Step 2: Second-Line Steroid-Sparing Agents

When corticosteroids fail to control disease, or when a steroid-sparing effect is needed, second-line agents include azathioprine, mycophenolate mofetil, leflunomide, and hydroxychloroquine. Evidence for these agents is largely derived from case series and expert opinion. In renal sarcoidosis, 45% of patients required additional immunosuppression after first-line corticosteroids, most commonly for relapse during tapering ^[49]B3b. In cutaneous sarcoidosis , hydroxychloroquine and sirolimus showed the highest response rates among non-biologic therapies (10% and 11%, respectively, though overall remission with topical therapy was only 11%) ^[53]C4.

Step 3: Biologic and Targeted Therapies

TNF‑α inhibitors are the best-studied biologic class. A systematic review and meta-analysis of 16 studies (level 1a) showed modest improvement in%‑predicted FVC with anti‑TNF agents (mean change 5.70%, 95% CI 1.61-9.78) ^[2]A1a. Infliximab is the most studied agent, with a positive direction of effect across all pulmonary and extrapulmonary outcomes ^[2]A1a. In cardiac sarcoidosis , TNF‑α inhibitors significantly increased ejection fraction (weighted mean difference, 95%), reduced prednisone dose at 6 months (WMD 9.20 mg/day, 95%) and at 12 months (WMD 6.40 mg/day, 95%), and decreased myocardial metabolic activity on PET ^[64]A1a. In neurosarcoidosis , infliximab achieved a 100% response rate at 12 months, with 80% of patients reaching ≤5 mg/day of prednisone, and a relapse rate of only 6% versus 56% with cyclophosphamide and 38% with methotrexate (p=0.06) ^[61]B2b. Adalimumab also showed benefit in neurosarcoidosis: 8 of 10 patients had a positive clinical and radiographic response ^[68]C4.

Other biologic and targeted agents include rituximab (limited data), anakinra, sarilumab, ustekinumab, and the novel immunomodulator efzofitimod, which targets neuropilin-2 and showed steroid-reducing effects in phase II but not phase III ^{[2]A1a [69]D5}. Tofacitinib, a JAK inhibitor, demonstrated a positive direction of effect across cutaneous and systemic outcomes in early trials ^[2]A1a. For refractory neurosarcoidosis, IL‑6 inhibitors (e.g., tocilizumab ) are increasingly used based on expert consensus ^[73]D5.

Warning: TNF‑α inhibitors can paradoxically induce sarcoidosis-like reactions. In patients with inflammatory bowel disease, infliximab, adalimumab, and golimumab triggered sarcoidosis-like lesions after a median of 27.5 months of exposure; management required discontinuation of the TNF inhibitor and a course of corticosteroids, with complete resolution in 7 of 14 patients ^[74]C4. Similar paradoxical reactions have been reported in neurosarcoidosis ^{[20]C4 [67]C4}. Clinicians should suspect this entity when a patient on anti‑TNF therapy develops new granulomatous manifestations.

Step 4: Maintenance and Tapering

Once disease control is achieved, the goal is to taper to the lowest effective dose. In cardiac sarcoidosis, a maintenance dose of 5-10 mg/day of prednisone is associated with better survival than doses <5 mg/day or >10 mg/day (log-rank p=0.012) ^[71]B2b. Re-escalation before reaching maintenance dose was particularly harmful in the low-dose group (HR 19.41, 95% CI 2.71-138.5) ^[71]B2b. For patients on methotrexate, a prospective study of cardiac sarcoidosis showed that 91.7% remained in remission after a mean treatment duration of 44.6 months, supporting the feasibility of eventually discontinuing methotrexate after sustained remission ^[65]B2b.

Dosing and Monitoring Overview

Controversies and Guideline Disagreement

Pearl: Initiate methotrexate as first-line therapy for pulmonary sarcoidosis to avoid corticosteroid toxicity (PREDMETH level 1b); reserve TNF inhibitors, especially infliximab, for refractory cardiac, neurologic, or severe systemic disease, but remain vigilant for paradoxical sarcoidosis-like reactions ^{[60]A1b [2]A1a [64]A1a [74]C4}.

While pharmacologic therapy provides the backbone of treatment, the approach must be tailored to the specific organ system involved, as disease behavior, severity, and response to therapy differ substantially across pulmonary, cardiac, neurologic, ocular, and cutaneous manifestations.

Pulmonary Sarcoidosis

Corticosteroids remain first-line for patients with active pulmonary disease, but the pooled relapse prevalence after treatment reduction or discontinuation is 39% (95% CI 0.33-0.45) ^[11]A1a. Relapse risk is higher in advanced radiographic stages (OR 1.73-2.83 vs stage I) and in Black patients (OR 2.48 vs White) ^[11]A1a. For patients requiring second-line therapy, namilumab, an anti-GM-CSF monoclonal antibody, was evaluated in a phase 2 trial (RESOLVE-Lung) at 150 mg subcutaneously every 4 weeks, but it did not improve outcomes: rescue events occurred in 37.5% vs 23.5% (p=0.12), and the least squares mean change in FVC % predicted was -3.3 vs -2.9 ^[47]A1b. Other agents such as methotrexate , azathioprine , and infliximab are commonly used, though their specific doses are not reported in the provided evidence. FDG-PET/CT can identify active pulmonary inflammation and guide biopsy, assess multisystem involvement, and monitor treatment response, but standardized interpretation criteria are lacking ^[77]D5.

Cardiac Sarcoidosis

Management of cardiac sarcoidosis (CS) requires a multidisciplinary strategy combining immunosuppression with device therapy. Corticosteroids are first-line, but cumulative toxicities ( hypertension , diabetes, weight gain) have spurred interest in targeted therapies ^[48]D5. The interleukin-1 trap rilonacept is under investigation in the REPAIR-CS trial (NCT06660732), a randomized phase II study adding rilonacept to standard nonbiologic therapy for 24 weeks; the primary endpoint is improvement in myocardial inflammation by FDG-PET ^[48]D5. FDG-PET is central to both diagnosis and monitoring: it can detect early inflammatory disease before structural changes occur, and serial PET imaging may guide immunosuppressive therapy ^[10]D5[54]D5. For arrhythmia risk, guidelines recommend an implantable cardioverter-defibrillator (ICD) in patients with sustained ventricular arrhythmias or significant left ventricular dysfunction ^[34]D5. Isolated cardiac sarcoidosis (iCS) is the most diagnostically challenging form; diagnosis relies on multimodality imaging (CMR with LGE, FDG-PET) and exclusion of phenocopies, with electroanatomic mapping-guided biopsy improving histologic yield ^[9]D5[34]D5.

Neurosarcoidosis

High-dose corticosteroids are first-line for acute neurosarcoidosis, with acute response rates of 94.4% (17/18) ^[33]B3b. However, symptomatic patients, especially those with hypothalamic-pituitary involvement, often require two or more lines of maintenance therapy; TNF inhibitor regimens (e.g., infliximab ) are most often successful (66.7%, 8/12) ^[33]B3b. Despite improved or resolved imaging (94.7%), most symptomatic patients remain on corticosteroids and/or hormonal treatments at a median follow-up of 55 months, and they experience worse functional outcomes ( mRS 3 vs 1, p=0.027) and higher relapse risk (12/19 vs 3/12, p=0.048) compared with asymptomatic patients ^[33]B3b. For refractory cases, cyclophosphamide is used, though not dosed in the provided abstracts. Importantly, TNF inhibitors can paradoxically trigger a neurosarcoidosis-like reaction; a case report described a 25-year-old man with ankylosing spondylitis who developed acute CNS inflammation during adalimumab therapy, with sustained remission after drug withdrawal ^[20]C4. Clinicians should consider this iatrogenic etiology in patients on anti-TNF therapy who develop new neurologic symptoms.

Ocular Sarcoidosis

Anterior uveitis is typically managed with topical corticosteroids ; posterior or refractory disease requires systemic immunosuppression, often with methotrexate or TNF inhibitors . No specific doses or trial outcomes are reported in the provided evidence, but these agents are standard based on extrapolation from pulmonary and multisystem disease.

Cutaneous Sarcoidosis

Topical corticosteroids and intralesional steroid injections are first-line for localized lesions. For widespread or disfiguring disease, antimalarials such as hydroxychloroquine are used. Specific doses are not reported in the provided abstracts.

Drug/Modality Comparison Table

Pearl: In pulmonary sarcoidosis, relapse after treatment reduction is common (39%) and higher in advanced stages and Black patients; FDG-PET/CT can help guide therapy decisions, while in cardiac sarcoidosis, multimodality imaging and ICD placement are essential for risk stratification ^{[11]A1a[34]D5[77]D5}.

Building on the organ-specific management strategies, the prognosis of sarcoidosis spans a wide spectrum from spontaneous remission to progressive organ failure and death. The disease course is highly variable, with approximately 50-60% of patients experiencing spontaneous remission within 2-5 years, while others develop chronic, relapsing disease requiring long-term therapy ^[52]B3b. Overall mortality is estimated at 1-5%, but this figure rises substantially in patients with cardiac or advanced pulmonary involvement ^[7]C4[13]B2b.

Overall Prognosis and Mortality

Sarcoidosis-associated heart failure carries a particularly poor prognosis. In a propensity-matched nationwide cohort study, patients with sarcoidosis-related heart failure had a 1-year all-cause mortality of 12.9%, significantly higher than both dilated cardiomyopathy (8.6%; HR 1.51) and ischemic heart disease (9.7%; HR 1.58) ^[13]B2b. Isolated cardiac sarcoidosis , a rare but severe variant, is associated with lower left ventricular ejection fraction and poorer survival compared with multi-organ cardiac sarcoidosis ^[7]C4. Pulmonary fibrosis and pulmonary hypertension are the leading causes of death in chronic pulmonary sarcoidosis , though specific mortality rates from these complications were not reported in the available evidence.

Prognostic Factors

The following table summarizes factors associated with favorable versus poor outcomes, drawn from recent cohort and cluster analyses.

No widely validated prognostic scoring system exists for sarcoidosis. Cluster analysis has identified two main phenotypes: one with minimal extrapulmonary disease (92.6% of patients) and another with multi-organ involvement (7.4%), but cluster membership did not independently predict chronicity ^[52]B3b. Exploratory analysis suggested a third arthritis-predominant phenotype with higher chronicity risk, though stability was low ^[52]B3b.

Long-term Sequelae

Fatigue is one of the most common and debilitating long-term symptoms, affecting up to 70% of patients even after apparent disease remission. A randomized controlled trial demonstrated that both one-legged and two-legged cycling exercise training (40-minute sessions twice weekly for 8 weeks) significantly improved fatigue scores, muscle strength, and quality of life in patients with pulmonary sarcoidosis stages 2-4 ^[32]A1b. Pain, particularly arthralgia and chest pain, and psychological impact (anxiety, depression) are also frequently reported, though specific prevalence data were not provided in the reviewed studies.

Recurrence Risk

Relapse rates vary by organ system and treatment modality. In neurosarcoidosis, the overall relapse rate after first-line therapy was 30.7% (56% with cyclophosphamide , 6% with infliximab , 38% with methotrexate ; p=0.06) ^[61]B2b. For anterior visual pathway involvement, combination therapy with steroids and immunosuppressants reduced relapse to 16% compared with 40% for steroids alone ^[6]A1a. In cutaneous sarcoidosis , relapse occurred in 40% of patients, and 46% required long-term systemic therapy ^[53]C4. These data underscore the importance of sustained immunosuppression in high-risk patients and the need for individualized treatment duration.

Pearl: The strongest predictor of chronic disease is the presence of arthritis at diagnosis (OR 17.02), while isolated intrathoracic lymphadenopathy predicts a self-limited course (OR 0.17), these simple clinical features can guide counseling on prognosis and treatment intensity ^[52]B3b.

Given the variable prognosis described in the preceding section, disease behavior and treatment response are further modified by age, pregnancy, immune status, and race. Each of these populations requires tailored diagnostic and therapeutic approaches.

Pediatrics

Pediatric sarcoidosis is rare and often presents with a triad of bilateral hilar lymphadenopathy, uveitis, and skin lesions. An important differential in young children is Blau syndrome, an early-onset granulomatous disease associated with NOD2 mutations. Drug-induced sarcoidosis-like reactions (DISR) can mimic systemic sarcoidosis; dupilumab, a monoclonal antibody used for atopic dermatitis, has been reported to cause DISR in pediatric patients, with features including uveitis, optic neuritis , and bilateral hilar lymphadenopathy ^[22]D5. Discontinuation of dupilumab typically leads to favorable outcomes, though symptoms may worsen in some cases ^[22]D5. Awareness of this potential adverse effect is critical when evaluating a child with suspected sarcoidosis. First-line therapy for pediatric sarcoidosis remains prednisone 0.5-1 mg/kg/day, with steroid-sparing agents such as methotrexate reserved for relapsing or refractory disease. Growth and development should be monitored closely due to the potential long-term effects of corticosteroids.

Pregnancy

Sarcoidosis often improves during pregnancy, likely due to hormonal shifts, but postpartum flares are common. Management must balance maternal disease control with fetal safety. Prednisone is the corticosteroid of choice because it is extensively metabolized by placental 11β-hydroxysteroid dehydrogenase, limiting fetal exposure; doses of 0.5-1 mg/kg/day are used for active disease. Methotrexate and mycophenolate mofetil are contraindicated due to teratogenicity and should be stopped at least 3 months before conception. Azathioprine and hydroxychloroquine are considered safer alternatives if immunosuppression is needed. Delivery planning should involve a multidisciplinary team, as cardiac sarcoidosis may pose peripartum arrhythmia risks. Breastfeeding is safe with prednisone doses below 20 mg/day; higher doses require a 4-hour delay after the dose. No data from the provided references inform pregnancy-specific outcomes, and guidelines are based on expert opinion.

Elderly

Elderly-onset sarcoidosis (age >65 years) is increasingly recognized and may present with atypical features such as fatigue, weight loss, and pulmonary fibrosis rather than classic Löfgren syndrome. Diagnostic delay is common because symptoms are attributed to aging or comorbidities. Corticosteroid doses should be reduced by 25-50% initially (e.g., prednisone 0.3-0.5 mg/kg/day) due to increased risk of osteoporosis, diabetes, and infection. Bone density monitoring and prophylaxis for steroid-induced osteoporosis are mandatory. Cardiac and neurologic involvement should be aggressively sought because these patients have higher morbidity from arrhythmias and neurocognitive deficits. The provided references do not contain specific elderly data, so management relies on extrapolation from younger cohorts.

Immunocompromised Patients

Sarcoidosis can occur in immunocompromised hosts, including those on biologic therapies or post-transplant. The development of granulomatous inflammation in this setting may be a paradoxical reaction to tumor necrosis factor (TNF) inhibitors (e.g., infliximab , adalimumab ) or other immune-modulating agents. Presentation is often atypical, with isolated cutaneous or pulmonary nodules. Immunosuppressive therapy should be reduced or discontinued if a drug-induced sarcoidosis-like reaction is suspected. In transplant recipients, the differential diagnosis includes infection (e.g., tuberculosis, fungal disease), and tissue biopsy is essential. Management of sarcoidosis in this population requires close collaboration with the transplant team to avoid graft rejection. Specific data from the provided references are lacking; clinical decisions should be individualized.

Racial and Ethnic Disparities

African American patients have a higher incidence of sarcoidosis, more severe pulmonary involvement, and greater mortality compared with White patients. In a Japanese case-control study, sarcoidosis was strongly associated with a personal history of immune-mediated inflammatory diseases (odds ratio 3.05, 95%) and a family history of sarcoidosis (odds ratio 21.30, 95%) ^[81]B3b. These findings suggest that genetic and environmental factors contribute to disease expression across populations. Clinicians should maintain a lower threshold for screening and aggressive treatment in high-risk racial groups, particularly African Americans, although no specific therapeutic modifications are validated in the provided references.

Pearl: In pediatric patients receiving dupilumab, unexplained uveitis, optic neuritis, or hilar adenopathy should prompt consideration of drug-induced sarcoidosis-like reaction; discontinuation of the offending agent is often diagnostic and therapeutic ^[22]D5.

Special populations require tailored management ; the evidence guiding these decisions derives from key trials that have shaped sarcoidosis treatment paradigms. The past decade has produced randomized data challenging long‑standing dogma, particularly around first‑line therapy and corticosteroid minimization.

PREDMETH: First‑Line Prednisone or Methotrexate ?

The PREDMETH trial (^[60]A1b, published 2025) is the first randomized noninferiority study comparing prednisone and methotrexate as initial therapy for pulmonary sarcoidosis . One hundred thirty‑eight treatment‑naïve patients were randomized 1:1 to a prespecified schedule of either drug. The primary endpoint, mean change in percentage of predicted FVC at 24 weeks, was 6.75 percentage points (95% CI 4.50-8.99) for prednisone and 6.11 percentage points (95% CI 3.72-8.50) for methotrexate. The adjusted between‑group difference was -1.17 percentage points (95% CI -4.27 to 1.93), meeting the noninferiority margin of 5 percentage points. Adverse events were similar in frequency, but the profile differed: prednisone caused weight gain, insomnia, and increased appetite; methotrexate caused nausea, fatigue, and liver‑function abnormalities. Clinical impact: Methotrexate is now a viable first‑line alternative, shifting the conversation from “corticosteroids first” to shared decision‑making based on side‑effect profile.

PRESTIGE: Cardiac Sarcoidosis and Methotrexate

The PRESTIGE study (^[84]B2b) prospectively treated 59 patients with active cardiac sarcoidosis using a 6‑month regimen of prednisolone (PSL). Median cardiac metabolic activity (CMA) dropped from 203.3 to 1.0 (P < 0.001). The 11 poor responders or those with recurrence were randomized to methotrexate or repeat PSL for another 6 months. Neither group showed significant further CMA reduction, and methotrexate was comparable to repeat PSL. Clinical impact: PSL is potent for initial control; methotrexate does not appear superior to a second PSL course in refractory cases, but the small sample limits conclusions.

Corticosteroid‑Sparing and Steroid Pulse Trials

A randomized trial of methylprednisolone pulse (15 mg/kg/day × 3 days) followed by oral prednisone versus oral prednisone alone for sarcoidosis tubulointerstitial nephritis (^[85]A1b) enrolled 40 patients. The primary endpoint, doubling of eGFR at 3 months, was achieved in 80% of the prednisone‑alone group versus 50% of the pulse group. Median eGFR at 3 months was similar (45 vs 46 mL/min/1.73 m²). Clinical impact: Intravenous pulse offers no renal benefit; standard oral prednisone suffices.

In the dexamethasone for quality‑of‑life trial (^[88]A1b, N = 16), low‑dose dexamethasone (1 mg daily, equivalent to 6.5 mg prednisone) improved fatigue scores (Checklist Individual Strength) from 106 to 86 at 6 months (P = 0.05) with no significant change in physical functioning. Clinical impact: Low‑dose corticosteroid may improve symptoms without the high‑dose burden.

Biologic Therapy: Infliximab , Sarilumab, and Rituximab

Infliximab in refractory sarcoidosis has been evaluated in two real‑world cohorts. Sakkat et al. (^[86]B3b, N = 33) reported treatment success in 100% of CNS (95% CI 54.1-100), 91.7% of cutaneous, and 78.6% of pulmonary cases, with a 50% prednisone dose reduction. Rivière et al. (^[90]B3b, N = 55) showed complete or partial response in 45% and 25% respectively, with highest response in CNS (OR 17) and ocular‑cardiac‑cutaneous‑CNS clusters (OR 7.4). Relapse after discontinuation occurred in 4 of 7 patients who stopped infliximab. Clinical impact: Infliximab is effective for refractory disease, especially neurologic and cutaneous, but relapse is common on cessation. Serious infections occurred in 36% of patients.

Sarilumab (IL‑6 receptor antagonist) was tested in a phase II withdrawal trial (^[83]A1b, N = 15). No meaningful signal was observed: 4 of 15 (26.7%) discontinued due to worsening during open‑label period, and only 1 of 8 placebo patients flared. Clinical impact: No evidence currently supports IL‑6 blockade for sarcoidosis.

Rituximab for CNS sarcoidosis (^[62]B2b, N = 19) failed in 73.7% (14/19), with median time to relapse 7.0 months. A small subset, those with multiple cranial neuropathies , may benefit. Clinical impact: Rituximab is not recommended as first‑ or second‑line therapy for neurosarcoidosis .

Comparative Effectiveness in Neurosarcoidosis

Gomez et al. (^[61]B2b) compared cyclophosphamide , infliximab, and methotrexate as first‑line therapy for neurosarcoidosis (N = 52). Relapse rates were 56% for cyclophosphamide, 6% for infliximab, and 38% for methotrexate (P = 0.06). At 12 months, response rate was 100% for infliximab, 89% for cyclophosphamide, and 87% for methotrexate. Infliximab had the highest proportion of patients reaching ≤5 mg/day prednisone (80%, P = 0.07). Infections were more frequent with cyclophosphamide (P = 0.01). Clinical impact: Infliximab appears superior for relapse prevention in neurosarcoidosis; cyclophosphamide carries higher infection risk.

Methotrexate Versus Azathioprine: Infection Risk

In a target trial emulation using Swedish registry data (^[87]B3b), methotrexate (N = 667) was associated with a 43% lower risk of infection at 6 months compared with azathioprine (N = 259): adjusted risk 6.8% vs 12.0%; RR 0.57 (95% CI 0.39-0.82); risk difference - (95% CI -8.5% to -1.8%). Clinical impact: When choosing between these agents, methotrexate may be preferred for lower infection risk, though randomized confirmation is lacking.

Controversies and Guideline Disagreement

Ongoing Trials

The PREDMETH trial design (^[89]D5) also includes a 2‑year follow‑up phase, and additional biomarker analyses may identify predictors of response. Larger studies of IL‑6 blockade and comparative trials of methotrexate versus mycophenolate for cardiac sarcoidosis are needed. The next section discusses how these trials translate into formal guideline recommendations.

Pearl: The PREDMETH trial proves methotrexate is noninferior to prednisone for first‑line pulmonary sarcoidosis, with a different side‑effect profile; infliximab is the best‑supported agent for refractory neurosarcoidosis, but relapse is common after discontinuation.

Building on the evidence from landmark trials, several professional societies have issued clinical practice guidelines to standardize the diagnosis and management of sarcoidosis. These documents, while largely concordant, reflect the heterogeneity of the disease and the frequent need for individualized decision-making.

Major Clinical Practice Guidelines

The table below summarizes the most influential current guidelines relevant to sarcoidosis care.

Patient Resources and Clinical Tools

The ERS guideline ^[92]A1c included patients in its task force, reflecting a growing emphasis on shared decision-making. Patient advocacy organizations such as the Foundation for Sarcoidosis Research and WASOG offer educational materials and support networks. For monitoring pulmonary sarcoidosis , the St. George's Respiratory Questionnaire (SGRQ) has been validated and correlates with FVC, dyspnea scores, and 6-minute walk distance; a change of 4 points is considered clinically meaningful ^[95]B2c. The WASOG criteria ^{[96]B3b[98]B2b} provide a standardized framework for classifying organ involvement in both clinical practice and trials.

Key Recommendations and Limitations

Both the ATS and ERS guidelines acknowledge that most recommendations are conditional due to very low-quality evidence ^{[92]A1c[93]A1c}. No major disagreements exist between the two; rather, they are complementary, ATS focuses on diagnosis, ERS on treatment. Clinicians should note that the diagnosis of sarcoidosis is never fully secure ^[93]A1c, and treatment decisions must weigh organ-specific risk, symptom burden, and patient preference. The WASOG criteria, while widely used, have not been prospectively validated in all populations ^[98]B2b.

Pearl: When applying guidelines, remember that sarcoidosis is a diagnosis of exclusion; the ATS guideline emphasizes that no single test is diagnostic, and clinical judgment remains paramount, especially when histology is unavailable or atypical ^[93]A1c.